The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Open accessAbstract
The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided recommendations for diagnostic and therapeutic procedures. The Panel covered all fields of expertise in neuro-oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical oncologists and clinical trial experts. The task made clearer and more transparent choices about outcomes considered most relevant through searching the references considered most relevant and evaluating their value. The scientific evidence of papers collected from the literature was evaluated and graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given accordingly. The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Self-citationBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Self-citationJiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717
An extent of resection threshold for newly diagnosed glioblastomas: Clinical article
Sanai, N., Polley, M.-Y., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of Neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,646
Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,611
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., VandenBerg, S., McDermott, M. W., & Berger, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9337 · Cited by 1,283
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Weller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
Roa, W., Brasher, P. M. A., Bauman, G., Anthes, M., Bruera, E., Chan, A., Fisher, B., Fulton, D., Gulavita, S., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 904
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Mutational landscape and clonal architecture in grade II and III gliomas
Suzuki, H., Aoki, K., Chiba, K., Sato, Y., Shiozawa, Y., Shiraishi, Y., Shimamura, T., Niida, A., Motomura, K., Ohka, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3273 · Cited by 831
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
McGirt, M. J., Chaichana, K. L., Gathinji, M., Attenello, F. J., Than, K., Olivi, A., Weingart, J. D., Brem, H., & Quiñones-Hinojosa, A. R. (2009) · Journal of Neurosurgery · doi:10.3171/2008.4.17536 · Cited by 809
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Radiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 772
Jenkins, R. B., Blair, H., Ballman, K. V., Giannini, C., Arusell, R. M., Law, M., Flynn, H., Passe, S., Felten, S., Brown, P. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1796 · Cited by 763
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Weller, M., van den Bent, M., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Cohen-Jonathan-Moyal, E., Frappaz, D., Henriksson, R., Balana, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70011-7 · Cited by 750
van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Shaw, E., Arusell, R., Scheithauer, B., O’Fallon, J., O’Neill, B., Dinapoli, R., Nelson, D., Earle, J., Jones, C., Cascino, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.126 · Cited by 730
Clonal evolution of glioblastoma under therapy
Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3590 · Cited by 720
Self-citationvan den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
Jakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgård, G., & Solheim, O. (2012) · JAMA · doi:10.1001/jama.2012.12807 · Cited by 641
Stupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Louis, D. N., Perry, A., Burger, P., Ellison, D. W., Reifenberger, G., von Deimling, A., Aldape, K., Brat, D., Collins, V. P., Eberhart, C., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12171 · Cited by 580
MGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 579
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Højfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse, B. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4293 · Cited by 535
Seizure characteristics and control following resection in 332 patients with low-grade gliomas
Chang, E. F., Potts, M. B., Keles, G. E., Lamborn, K. R., Chang, S. M., Barbaro, N. M., & Berger, M. S. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/2/0227 · Cited by 526
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505
Lai, A., Tran, A., Nghiemphu, P. L., Pope, W. B., Solis, O. E., Selch, M., Filka, E., Yong, W. H., Mischel, P. S., Liau, L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2729 · Cited by 458
Claus, E. B., Horlacher, A., Hsu, L., Schwartz, R. B., Dello‐Iacono, D., Talos, F., Jolesz, F. A., & Black, P. M. (2005) · Cancer · doi:10.1002/cncr.20867 · Cited by 454
Reuss, D. E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., Schweizer, L., Korshunov, A., Jones, D. T. W., Hovestadt, V., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1370-3 · Cited by 449
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Piunti, A., Hashizume, R., Morgan, M. A., Bartom, E. T., Horbinski, C. M., Marshall, S. A., Rendleman, E. J., Ma, Q., Takahashi, Y.-H., Woodfin, A. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4296 · Cited by 445
Response Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 435
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review
Laperriere, N., Zuraw, L., & Cairncross, G. (2002) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00078-6 · Cited by 424
Bao, Z.-S., Chen, H.-M., Yang, M.-Y., Zhang, C.-B., Yu, K., Ye, W.-L., Hu, B.-Q., Yan, W., Zhang, W., Akers, J., et al. (2014) · Genome Research · doi:10.1101/gr.165126.113 · Cited by 409
Self-citationCairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 402
van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 394
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Leighton, C., Fisher, B., Bauman, G., Depiero, S., Stitt, L., MacDonald, D., & Cairncross, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1294 · Cited by 365
Shaw, E. G., Wang, M., Coons, S. W., Brachman, D. G., Buckner, J. C., Stelzer, K. J., Barger, G. R., Brown, P. D., Gilbert, M. R., & Mehta, M. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8598 · Cited by 355
Wiestler, B., Capper, D., Holland-Letz, T., Korshunov, A., von Deimling, A., Pfister, S. M., Platten, M., Weller, M., & Wick, W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1156-z · Cited by 346
Wijnenga, M. M. J., French, P. J., Dubbink, H. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Smits, M., Gahrmann, R., Rutten, G.-J., Verheul, J. B., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox176 · Cited by 334
Integrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, E. Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 329
Self-citationShaw, E. G., Berkey, B., Coons, S. W., Bullard, D., Brachman, D., Buckner, J. C., Stelzer, K. J., Barger, G. R., Brown, P. D., Gilbert, M. R., et al. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/109/11/0835 · Cited by 324
Pekmezci, M., Rice, T., Molinaro, A. M., Walsh, K. M., Decker, P. A., Hansen, H., Sicotte, H., Kollmeyer, T. M., McCoy, L. S., Sarkar, G., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1690-1 · Cited by 319
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Kim, J., Lee, I.-H., Cho, H. J., Park, C.-K., Jung, Y.-S., Kim, Y., Nam, S. H., Kim, B. S., Johnson, M. D., Kong, D.-S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.013 · Cited by 314
Weller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Löffler-Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
Pace, A., Dirven, L., Koekkoek, J. A. F., Golla, H., Fleming, J., Rudà, R., Marosi, C., Rhun, E. L., Grant, R., Oliver, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30345-5 · Cited by 297
Ius, T., Isola, M., Budai, R., Pauletto, G., Tomasino, B., Fadiga, L., & Skrap, M. (2012) · Journal of Neurosurgery · doi:10.3171/2012.8.jns12393 · Cited by 295
Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Di Stefano, A. L., Fucci, A., Frattini, V., Labussiere, M., Mokhtari, K., Zoppoli, P., Marie, Y., Bruno, A., Boisselier, B., Giry, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2199 · Cited by 293
Cha, S., Lupo, J. M., Chen, M.-H., Lamborn, K. R., McDermott, M. W., Berger, M. S., Nelson, S. J., & Dillon, W. P. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0484 · Cited by 290
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome
Kaloshi, G., Benouaich-Amiel, A., Diakite, F., Taillibert, S., Lejeune, J., Laigle-Donadey, F., Renard, M.-A., Iraqi, W., Idbaih, A., Paris, S., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000262034.26310.a2 · Cited by 286
Molecular imaging of gliomas with PET: Opportunities and limitations
la Fougere, C., Suchorska, B., Bartenstein, P., Kreth, F.-W., & Tonn, J.-C. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor054 · Cited by 274
Sahm, F., Reuss, D., Koelsche, C., Capper, D., Schittenhelm, J., Heim, S., Jones, D. T. W., Pfister, S. M., Herold-Mende, C., Wick, W., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1326-7 · Cited by 272
Duffau, H. (2016) · Acta Neurochirurgica · doi:10.1007/s00701-015-2621-3 · Cited by 269
TERT promoter mutations in primary and secondary glioblastomas
Nonoguchi, N., Ohta, T., Oh, J.-E., Kim, Y.-H., Kleihues, P., & Ohgaki, H. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1163-0 · Cited by 267
EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma
Fan, Q.-W., Cheng, C. K., Gustafson, W. C., Charron, E., Zipper, P., Wong, R. A., Chen, J., Lau, J., Knobbe-Thomsen, C., Weller, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.004 · Cited by 262
Self-citationForst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0345 · Cited by 253
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Brada, M., Stenning, S., Gabe, R., Thompson, L. C., Levy, D., Rampling, R., Erridge, S., Saran, F., Gattamaneni, R., Hopkins, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1932 · Cited by 249
Extent of Surgical Resection Predicts Seizure Freedom in Low-Grade Temporal Lobe Brain Tumors
Englot, D. J., Han, S. J., Berger, M. S., Barbaro, N. M., & Chang, E. F. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31823c3a30 · Cited by 234
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
International Cancer Genome Consortium PedBrain Tumor Project (2016) · Nature Medicine · doi:10.1038/nm.4204 · Cited by 233
Wick, W., Roth, P., Hartmann, C., Hau, P., Nakamura, M., Stockhammer, F., Sabel, M. C., Wick, A., Koeppen, S., Ketter, R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now133 · Cited by 227
Iwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
Self-citationSurgery of low-grade gliomas: towards a ‘functional neurooncology’
Duffau, H. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283305996 · Cited by 220
Combined analysis of TERT , EGFR , and IDH status defines distinct prognostic glioblastoma classes
Labussière, M., Boisselier, B., Mokhtari, K., Di Stefano, A.-L., Rahimian, A., Rossetto, M., Ciccarino, P., Saulnier, O., Paterra, R., Marie, Y., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000814 · Cited by 218
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
Parker, B. C., Annala, M. J., Cogdell, D. E., Granberg, K. J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67144 · Cited by 215
Self-citationMGMT methylation: A marker of response to temozolomide in low‐grade gliomas
Everhard, S., Kaloshi, G., Crinière, E., Benouaich‐Amiel, A., Lejeune, J., Marie, Y., Sanson, M., Kujas, M., Mokhtari, K., Hoang‐Xuan, K., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21044 · Cited by 215
Kreth, F. W., Thon, N., Simon, M., Westphal, M., Schackert, G., Nikkhah, G., Hentschel, B., Reifenberger, G., Pietsch, T., Weller, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt388 · Cited by 209
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
Labussière, M., Di Stefano, A. L., Gleize, V, Boisselier, B., Giry, M., Mangesius, S., Bruno, A., Paterra, R., Marie, Y., Rahimian, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.538 · Cited by 202
Efficacy of anti-epileptic drugs in patients with gliomas and seizures
Breemen, M. S. M., Rijsman, R. M., Taphoorn, M. J. B., Walchenbach, R., Zwinkels, H., & Vecht, C. J. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5156-9 · Cited by 201
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
Zhang, W., Zhang, J., Hoadley, K., Kushwaha, D., Ramakrishnan, V., Li, S., Kang, C., You, Y., Jiang, C., Song, S. W., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos089 · Cited by 196
Self-citationWiestler, B., Capper, D., Sill, M., Jones, D. T. W., Hovestadt, V., Sturm, D., Koelsche, C., Bertoni, A., Schweizer, L., Korshunov, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1315-x · Cited by 194
Wang, Z., Zhang, C., Liu, X., Wang, Z., Sun, L., Li, G., Liang, J., Hu, H., Liu, Y., Zhang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196310 · Cited by 193
Self-citationMolecular neuro-oncology in clinical practice: a new horizon
Weller, M., Pfister, S. M., Wick, W., Hegi, M. E., Reifenberger, G., & Stupp, R. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70168-2 · Cited by 189
Gorlia, T., Stupp, R., Brandes, A. A., Rampling, R. R., Fumoleau, P., Dittrich, C., Campone, M. M., Twelves, C. C., Raymond, E., Hegi, M. E., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.004 · Cited by 186
Yang, P., Wang, Y., Peng, X., You, G., Zhang, W., Yan, W., Bao, Z., Wang, Y., Qiu, X., & Jiang, T. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1103-9 · Cited by 183
Self-citationMolecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel
Zacher, A., Kaulich, K., Stepanow, S., Wolter, M., Köhrer, K., Felsberg, J., Malzkorn, B., & Reifenberger, G. (2017) · Brain Pathology · doi:10.1111/bpa.12367 · Cited by 181
Clarke, J. L., Iwamoto, F. M., Sul, J., Panageas, K., Lassman, A. B., DeAngelis, L. M., Hormigo, A., Nolan, C. P., Gavrilovic, I., Karimi, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7944 · Cited by 179
Wheeler, L. A., Manzanera, A. G., Bell, S. D., Cavaliere, R., McGregor, J. M., Grecula, J. C., Newton, H. B., Lo, S. S., Badie, B., Portnow, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now002 · Cited by 172
Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R.-D., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9104 · Cited by 166
Fisher, B. J., Hu, C., Macdonald, D. R., Lesser, G. J., Coons, S. W., Brachman, D. G., Ryu, S., Werner-Wasik, M., Bahary, J.-P., Liu, J., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.11.012 · Cited by 163
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C., Yao, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5683 · Cited by 162
Self-citationEpilepsy meets cancer: when, why, and what to do about it?
Weller, M., Stupp, R., & Wick, W. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70266-8 · Cited by 161
Wick, W., Gorlia, T., Bady, P., Platten, M., van den Bent, M. J., Taphoorn, M. J. B., Steuve, J., Brandes, A. A., Hamou, M.-F., Wick, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3153 · Cited by 159
Kawaguchi, T., Sonoda, Y., Shibahara, I., Saito, R., Kanamori, M., Kumabe, T., & Tominaga, T. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2201-2 · Cited by 158
Chinnaiyan, P., Won, M., Wen, P. Y., Rojiani, A. M., Werner‐Wasik, M., Shih, H. A., Ashby, L. S., Yu, H.-H. M., Stieber, V. W., Malone, S. C., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox209 · Cited by 158
Dresemann, G. P., Weller, M., Rosenthal, M. A., Wedding, U., Wagner, W., Engel, E., Heinrich, B., Mayer‐Steinacker, R., Krarup‐Hansen, A., Fluge, Ø., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9976-3 · Cited by 156
Yan, W., Zhang, W., You, G., Bao, Z., Wang, Y., Liu, Y., Kang, C., You, Y., Wang, L., & Jiang, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030339 · Cited by 135
Self-citationClarke, J. L., Ennis, M. M., Yung, W. K. A., Chang, S., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor110 · Cited by 120
Yang, P., Cai, J., Yan, W., Zhang, W., Wang, Y., Chen, B., Li, G., Li, S., Wu, C., Yao, K., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now021 · Cited by 119
Self-citationTime course of imaging changes of GBM during extended bevacizumab treatment
Ananthnarayan, S., Bahng, J., Roring, J., Nghiemphu, P. L., Lai, A., Cloughesy, T. F., & Pope, W. B. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9573-x · Cited by 112
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Chan, A. K., Yao, Y., Zhang, Z., Chung, N. Y., Liu, J. S.-M., Li, K. K., Shi, Z., Chan, D. T. M., Poon, W. S., Zhou, L., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.94 · Cited by 111
Self-citationWijnenga, M. M. J., Dubbink, H. J., French, P. J., Synhaeve, N. E., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Dirven, C. M. F., Vincent, A. J. P. E., & van den Bent, M. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1781-z · Cited by 103
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Lee, Y., Koh, J., Kim, S., Won, J., Park, C., Choi, S. H., & Park, S. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0465-1 · Cited by 101
Huse, J. T., Diamond, E. L., Wang, L., & Rosenblum, M. K. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1359-y · Cited by 97
Self-citationSurgery Insight: the role of surgery in the management of low-grade gliomas
Pouratian, N., Asthagiri, A. R., Jagannathan, J., Shaffrey, M. E., & Schiff, D. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0634 · Cited by 96
Kreth, S., Limbeck, E., Hinske, L. C., Schütz, S. V., Thon, N., Hoefig, K. P., Egensperger, R., & Kreth, F. W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1081-1 · Cited by 94
Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomas
Kujas, M., Lejeune, J., Benouaich‐Amiel, A., Crinière, E., Laigle–Donadey, F., Marie, Y., Mokhtari, K., Polivka, M., Bernier, M., Chrétien, F. C., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20543 · Cited by 89
Wiestler, B., Capper, D., Hovestadt, V., Sill, M., Jones, D., Hartmann, C. J., Felsberg, J., Platten, M., Feiden, W., Keyvani, K., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou138 · Cited by 88
Chen, L., Voronovich, Z. A., Clark, K., Hands, I., Mannas, J., Walsh, M., Nikiforova, M. N., Durbin, E. B., Weiss, H. L., & Horbinski, C. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou097 · Cited by 88
Self-citationPhase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Kalpathy–Cramer, J., Chandra, V., Da, X., Ou, Y., Emblem, K. E., Muzikansky, A., Cai, X., Douw, L., Evans, J. G., Dietrich, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2332-5 · Cited by 84
Cortical mapping by functional magnetic resonance imaging in patients with brain tumors
Majos, A., Tybor, K., Stefańczyk, L., & Goraj, B. M. (2004) · European Radiology · doi:10.1007/s00330-004-2565-0 · Cited by 78
Cai, J., Yang, P., Zhang, C., Zhang, W., Liu, Y., Bao, Z., Liu, X., Du, W., Wang, H., Jiang, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1838 · Cited by 76
Self-citationSupratotal resection of diffuse gliomas – an overview of its multifaceted implications
Yordanova, Y. N., & Duffau, H. (2017) · Neurochirurgie · doi:10.1016/j.neuchi.2016.09.006 · Cited by 75
Fujii, Y., Muragaki, Y., Maruyama, T., Nitta, M., Saito, T., Ikuta, S., Iseki, H., Hongo, K., & Kawamata, T. (2017) · Journal of neurosurgery · doi:10.3171/2017.3.jns162383 · Cited by 69
The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas
Patel, T., Bander, E. D., Venn, R. A., Powell, T. M., Cederquist, G., Schaefer, P. M., Puchi, L. A., Akhmerov, A., Ogilvie, S. Q., Reiner, A. S., et al. (2017) · Neurosurgery · doi:10.1093/neuros/nyx265 · Cited by 68
Buckner, J. C., Pugh, S. L., Shaw, E. G., Gilbert, M. R., Barger, G. R., Coons, S. W., Ricci, P. E., Bullard, D. E., Brown, P. D., Stelzer, K. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2000 · Cited by 66
Talacchi, A., Turazzi, S., Locatelli, F., Sala, F., Beltramello, A., Alessandrini, F., Manganotti, P., Lanteri, P., Gambin, R., Ganau, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0193-x · Cited by 65
Cai, J., Chen, J., Zhang, W., Yang, P., Zhang, C., Li, M., Yao, K., Wang, H., Li, Q., Jiang, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3906 · Cited by 65
Self-citationZhang, C., Bao, Z., Wang, H., Yan, W., Liu, Y., Li, M., Zhang, W., Chen, L., & Jiang, T. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1519-9 · Cited by 64
Self-citationSurgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery
Ryken, T. C., Frankel, B. M., Julien, T., & Olson, J. J. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9614-5 · Cited by 59
Bénit, C. P., & Vecht, C. J. (2015) · Neuro-Oncology Practice · doi:10.1093/nop/npv038 · Cited by 55
Advances in the Surgical Management of Low-Grade Glioma
Hollon, T. C., Hervey‐Jumper, S. L., Sagher, O., & Orringer, D. A. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.007 · Cited by 54
Spena, G., D’Agata, F., Panciani, P. P., Buglione, M., & Fontanella, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080916 · Cited by 42
Li, S., Yan, C., Huang, L. F., Qiu, X., Wang, Z., & Jiang, T. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor185 · Cited by 39
Self-citationChung, C. D., Metser, U., & Ménard, C. M. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.002 · Cited by 38
Zhang, Z.-Y., Chan, A. K., Ding, X., Qin, Z., Hong, C. S., Chen, L., Zhang, X., Zhao, F., Wang, Y., Wang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4549 · Cited by 38
Self-citationEvaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours
Haque, F., Varlet, P., Puntonet, J., Storer, L. C. D., Bountali, A., Rahman, R., Grill, J., Carcaboso, A. M., Jones, C., Layfield, R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0449-1 · Cited by 38
Updated Therapeutic Strategy for Adult Low-Grade Glioma Stratified by Resection and Tumor Subtype
Nitta, M., Muragaki, Y., Maruyama, T., Iseki, H., Ikuta, S., KONISHI, Y., Saito, T., Tamura, M., CHERNOV, M., Watanabe, A., et al. (2013) · Neurologia medico-chirurgica · doi:10.2176/nmc.53.447 · Cited by 32
Anaplastic glioma: current treatment and management
Rhun, É. L., Taillibert, S., & Chamberlain, M. C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1042455 · Cited by 26
Fisher, B. J., Lui, J., Macdonald, D., Lesser, G. J., Coons, S. W., Brachman, D. G., Ryu, S., Werner‐Wasik, M., Bahary, J.-P., Hu, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2008 · Cited by 25
Chamberlain, M. C. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1714-9 · Cited by 24
Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies
Johnson, D. R., & Galanis, E. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.06.010 · Cited by 23
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
Li, M., Wang, Y., Cai, J., Zhang, C., Wang, K., Cheng, W., Liu, Y., Zhang, W., & Jiang, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130872 · Cited by 21
Self-citationTreatment of Anaplastic Glioma
Wick, W., Wiestler, B., & Platten, M. (2014) · Cancer treatment and research · doi:10.1007/978-3-319-12048-5_6 · Cited by 19
The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma
Youland, R. S., Kreofsky, C. R., Schomas, D. A., Brown, P. D., Buckner, J. C., & Laack, N. N. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2599-1 · Cited by 19
Recent Technical Advances and Indications for Radiation Therapy in Low-Grade Glioma
Chan, M. D. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.001 · Cited by 10
Labussière, M., Boisselier, B., Mokhtari, K., Stefano, A. L. D., Rahimian, A., Saulnier, O., Paterra, R., Finocchiaro, G., Marie, Y., & Sanson, M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou174.49 · Cited by 4
Cited by
Clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Nam, D.-H., Ram, Z., Poon, W.-S., Wang, J., Boldbaatar, D., Mao, Y., Ma, W., Mao, Q., You, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.050 · Cited by 431
Self-citationComprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas
Zhao, Z., Meng, F., Wang, W., Wang, Z., Zhang, C., & Jiang, T. (2017) · Scientific Data · doi:10.1038/sdata.2017.24 · Cited by 287
Self-citationWang, H., Chen, Z., Wang, S., Gao, X., Qian, M., Qiu, W., Zhang, Z., Zhang, S., Qi, Y., Sun, X., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12623 · Cited by 20
Self-citation
Metadata
- Authors
- Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., Qiu, X., Wang, W., Li, W., Yao, Y., Li, S., Li, S., Wu, A., Sai, K., Bai, H., Li, G., Chen, B., Yao, K., Wei, X., Liu, X., Zhang, Z., Dai, Y., Lv, S., Wang, L., Lin, Z., Dong, J., Xu, G., Ma, X., Cai, J., Zhang, W., Wang, H., Chen, L., Zhang, C., Yang, P., Yan, W., Liu, Z., Hu, H., Chen, J., Liu, Y., Yang, Y., Wang, Z., Wang, Z., Wang, Y., You, G., Han, L., Bao, Z., Liu, Y., Wang, Y., Fan, X., Liu, S., Liu, X., Wang, Y., & Wang, Q.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 375
- Issue
- 2
- Pages
- 263-273
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2295059886
- Cited by
- 607
- References
- 173
- FWCI
- 22.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.